Skye Bioscience, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing G-protein-coupled receptor modulators for obesity and metabolic health. Form 8-K reports cover financial results, corporate updates, Reg FD clinical communications for nimacimab and the CBeyond program, and material events tied to executive transitions, equity compensation and Nasdaq listing-compliance matters.
The company's proxy materials address annual meeting voting, director elections, executive compensation, pay-versus-performance tables, equity awards and incentive-plan governance. Compensation-related filings also describe stock-option repricing under Skye equity incentive plans and related common-stock disclosures.